TScan Therapeutics (NASDAQ:TCRX) Downgraded by HC Wainwright to “Neutral”

TScan Therapeutics (NASDAQ:TCRX) was downgraded by research analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a note issued to investors on Tuesday, Marketbeat Ratings reports. They currently have a $1.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 155.43% from the company’s previous close.

TCRX has been the topic of several other research reports. Needham & Company LLC restated a “buy” rating and issued a $6.00 price objective on shares of TScan Therapeutics in a research report on Tuesday, June 23rd. Lifesci Capital lowered shares of TScan Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of TScan Therapeutics in a report on Friday, July 17th. Wedbush downgraded shares of TScan Therapeutics from a “buy” rating to a “neutral” rating and set a $1.00 price target on the stock. in a report on Wednesday, September 2nd. Finally, Benchmark restated a “buy” rating on shares of TScan Therapeutics in a research report on Thursday, August 13th. Two research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $2.67.

TScan Therapeutics Stock Performance

Shares of TCRX stock opened at $0.39 on Tuesday. The stock has a market cap of $26.54 million, a PE ratio of -0.43 and a beta of 1.07. The business has a 50-day simple moving average of $0.82 and a 200-day simple moving average of $0.98. The company has a quick ratio of 3.37, a current ratio of 3.37 and a debt-to-equity ratio of 0.31. TScan Therapeutics has a 52-week low of $0.35 and a 52-week high of $2.57.

TScan Therapeutics (NASDAQ:TCRX) last posted its earnings results on Wednesday, August 12th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.02. The firm had revenue of $1.05 million for the quarter, compared to analyst estimates of $1.88 million. TScan Therapeutics had a negative return on equity of 108.72% and a negative net margin of 1,655.35%. On average, equities analysts expect that TScan Therapeutics will post -1.11 EPS for the current year.

Institutional Investors Weigh In On TScan Therapeutics

Large investors have recently modified their holdings of the business. Public Employees Retirement System of Ohio acquired a new position in TScan Therapeutics during the second quarter worth about $36,000. Bank of America Corp DE acquired a new stake in TScan Therapeutics in the 2nd quarter valued at about $48,000. Landscape Capital Management L.L.C. acquired a new stake in TScan Therapeutics in the 2nd quarter valued at about $25,000. NewEdge Wealth LLC purchased a new position in TScan Therapeutics in the 2nd quarter worth approximately $90,000. Finally, BlackRock Inc. purchased a new position in TScan Therapeutics in the 2nd quarter worth approximately $975,000. Hedge funds and other institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.